Dianthus Therapeutics, Inc.
NASDAQDianthus Therapeutics enters the back half of September with an uncomfortable combination: the stock is down 9% on the week and 16% over the past month, yet short interest has quietly crept to 20% of the free float — and JP Morgan just stepped in with a fresh Overweight initiation. The short-interest story is the most important tension here. Bears hold a meaningful position — 20%…
Snapshot as of 20 Sept 2026
Dianthus Therapeutics enters the back half of September with an uncomfortable combination: the stock is down 9% on the week and 16% over the past month, yet short interest has quietly crept to 20% of the free float —…
Dianthus Therapeutics has cleared its earnings event with momentum intact — and the data since the print shows shorts retreating while institutional conviction holds firm. The most notable post-earnings shift is in…
Dianthus Therapeutics heads into tonight's earnings report with options traders at their most bullish in recent memory — while a large short base keeps the setup charged on both sides. The options signal is the…
Dianthus Therapeutics enters the week with a genuinely split picture: short interest is running at 15.6% of the free float — a meaningfully elevated position — yet the lending market is telling a completely different…
Dianthus Therapeutics reports today after market close with short sellers in retreat and analysts broadly constructive — but insider selling from the CFO adds a note of caution to an otherwise positive setup. The most…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for DNTH — free to start on ORTEX.
Sign up for free →Open DNTH on ORTEX